Indonesia Pharmaceutical Formulation Manufacturing Facility Feasibility Study, Pharma Manufacturing Market Analysis

Executive Viability Abstract

This feasibility study evaluates the establishment of a state-of-the-art pharmaceutical formulation facility in the West Java corridor, Indonesia. Capitalizing on the Jaminan Kesehatan Nasional (JKN) program and a domestic market valued at USD 7.8 billion, the project demonstrates a robust IRR of 19.4% under base-case assumptions, driven by strategic import substitution and high TKDN (Local Content) compliance.

## 1. Executive Feasibility Thesis The Indonesian pharmaceutical market is projected to reach IDR 145 Trillion (USD 9.4B) by 2026, yet 90% of Active Pharmaceutical Ingredients (APIs) remain imported. This project proposes a formulation facility focused on Oral Solid Dosage (OSD) and Liquid formulations to serve the high-volume generic segment. The core thesis relies on the government's 'Making Indonesia 4.0' roadmap, which provides tax holidays and preferential procurement for manufacturers achieving >40% TKDN (Tingkat Komponen Dalam Negeri). **Key Assumptions:** - **Target Market Size:** IDR 115 Trillion (Current addressable domestic market). - **Cost of Capital (WACC):** 10.5% (Reflecting Indonesia 10-year bond yield + 3.5% equity risk premium). - **Capacity Utilization:** 40% (Year 1), ramping to 85% by Year 5. - **Inflation/FX:** 3.5% inflation; USD/IDR stability within a 5% corridor. ## 2. Technical Feasibility & Operational Specifications The facility will be located in the Jababeka Industrial Estate (Cikarang), providing proximity to major logistics hubs and specialized waste treatment. - **Facility Footprint:** 12,000 sqm total, with 5,500 sqm dedicated Cleanroom (Class D/E). - **Production Lines:** - High-speed Tablet Press (400,000 units/hr). - Fluid Bed Granulator (600L capacity). - Automated Liquid Filling Line (120 bottles/min). - **Technology Stack:** Implementation of an Integrated Manufacturing Execution System (MES) for real-time batch recording, compliant with BPOM's CPOB (GMP) 2018 standards. - **Utilities:** Dedicated 2MVA power connection with N+1 redundancy via Caterpillar diesel generators; Purified Water (PW) system producing 2,000 L/hr. ## 3. Detailed Capital Expenditure (Capex) Total Estimated Capex: **USD 24,500,000** | Item | Unit Cost | Quantity | Total (USD) | Reasoning | | :--- | :--- | :--- | :--- | :--- | | **Land Acquisition** | $280 / sqm | 12,000 sqm | $3,360,000 | Current market rate in Cikarang industrial zone. | | **Civil Construction** | $1,100 / sqm | 8,000 sqm | $8,800,000 | Industrial grade with specialized floor epoxy and seismic reinforcements. | | **HVAC & Cleanroom** | $1,500 / sqm | 5,500 sqm | $8,250,000 | HEPA filtration and humidity control (RH <45% for effervescents). | | **Manufacturing Eq.** | $3,500,000 | 1 Lump | $3,500,000 | Core OSD and Liquid lines (European/Tier-1 Chinese blend). | | **Lab & QC Equipment** | $590,000 | 1 Set | $590,000 | HPLC, dissolution testers, and stability chambers. | ## 4. Realistic Operating Expenditure (Opex) Annualized Opex at 75% Capacity: **USD 14,200,000** - **Raw Materials (API/Excipients):** $9,200,000 (Based on 65% of COGS). Most APIs sourced from India/China with 5-10% import duty. - **Labor:** $1,440,000. Based on 200 staff; average monthly cost $600/head (including BPJS health/pension and UMK Bekasi allowance). - **Utilities:** $960,000. Electricity at $0.078/kWh; Water at $1.10/m3. - **Maintenance:** $735,000 (3% of equipment/civil value). - **Quality Assurance/Testing:** $450,000 (Regulatory audits and batch testing). - **Marketing & Admin:** $1,415,000 (Focusing on E-Katalog government tenders). ## 5. Financial Model & Sensitivity Range on ROI/IRR - **NPV (at 10.5%):** USD 12.8 Million - **Payback Period:** 5.4 Years - **Base Case IRR:** 19.4% ### Sensitivity Analysis Table | Case | Variable Change | Projected IRR | Impact Analysis | | :--- | :--- | :--- | :--- | | **Optimistic** | +10% Sales Price | 24.2% | High TKDN allows for premium pricing in Gov tenders. | | **Base** | No Change | 19.4% | Standard market absorption. | | **Pessimistic** | +15% API Cost | 13.1% | Significant IDR depreciation or supply chain disruption. | | **Yield Variation** | -5% Production Yield | 15.8% | Impacts of operational inefficiency or high rejection rates. | ## 6. Regulatory & Environmental Compliance Frameworks - **BPOM (CPOB 2018):** Full certification required before commercial distribution. Facility design must allow for unidirectional flow to prevent cross-contamination. - **Halal Certification (BPJPH):** Mandatory for all pharmaceutical products in Indonesia by 2024. This requires dedicated storage and separation of non-halal materials. - **Environmental (AMDAL/UKL-UPL):** Wastewater Treatment Plant (IPAL) must meet Permen LHK No. 5/2014 standards regarding chemical oxygen demand (COD) levels. - **TKDN (Local Content):** Target of >45% to secure 'priority' status in the LKPP E-Katalog for JKN supply. ## 7. Strategic Takeaways 1. **Location Advantage:** Cikarang offers the highest density of pharma talent and specialized technical support in Southeast Asia. 2. **Import Substitution:** By focusing on molecules with expired patents and high import volumes, the facility can capture the 35% margin currently lost to foreign distributors. 3. **Risk Mitigation:** To hedge against FX volatility affecting API imports, the facility should prioritize local excipient sourcing and maintain a 3-month raw material buffer. 4. **Scalability:** The modular cleanroom design allows for a 30% expansion in Phase 2 for injectable formulations without disrupting Phase 1 operations.